OMCL vs TLRY · P/E 90, rev $622.1M vs rev $915.5M
Omnicell Inc (OMCL) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Omnicell Inc (OMCL) is a health information services company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported OMCL revenue for 2026-06-30 was $622.1M. Net income was $35.6M. OMCL currently screens at market cap $1.80B and trailing P/E 89.9.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
OMCL currently screens at market cap $1.80B and trailing P/E 89.9. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the OMCL and TLRY stock pages for the full models.
Not investment advice.